The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Home Explore BioSpectrum Asia April 2023
View in Fullscreen

A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people. According to a latest report on malaria from the World Health Organisation (WHO), there were approximately 5.4 million cases and 9000 deaths in the region in 2021. The SEA region has nine countries where malaria is prevalent, and their contribution to the global burden of malaria cases is two per cent. India is the main contributor to the malaria cases in the region, accounting for 82.5 per cent of them, followed by Indonesia with 15.6 per cent, and Myanmar with 1.6 per cent. These three countries were responsible for almost all of the malaria cases in the region, making up 99.7 per cent of the total estimated cases. Governments, healthcare organisations, and communities are implementing innovative strategies, technologies, and programmes that can help curb the spread of malaria. Though these efforts were hampered because of COVID-19, in 2022, the WHO South-East Asia Region renewed its commitment to eliminate malaria by 2030, with countries pledging accelerated action and greater efforts at the sub-national and community levels. Other parts of Asia also progressed well. China was declared Malaria free in June 2021, after 70 years of fighting. In its fights against malaria, Asian countries have recently announced significant investment including a $1.9 million investment in February 2023 by Japan’s GHIT Fund for the research and development of a new malaria drug, and a $1 million contribution by Singapore’s Ministry of Health to the Global Fund to fight AIDS, TB, and Malaria, announced in December 2022. While observing World Malaria day on April 25, let’s explore the current status of Asia’s malaria elimination efforts, highlighting the progress made and strategies needed for a malaria-free future.

Like this book? You can publish your book online for free in a few minutes!
Share

Related Publications

Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by MMA Media, 2023-03-30 07:10:10

BioSpectrum Asia April 2023

A World Sans MALARIA
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people. According to a latest report on malaria from the World Health Organisation (WHO), there were approximately 5.4 million cases and 9000 deaths in the region in 2021. The SEA region has nine countries where malaria is prevalent, and their contribution to the global burden of malaria cases is two per cent. India is the main contributor to the malaria cases in the region, accounting for 82.5 per cent of them, followed by Indonesia with 15.6 per cent, and Myanmar with 1.6 per cent. These three countries were responsible for almost all of the malaria cases in the region, making up 99.7 per cent of the total estimated cases. Governments, healthcare organisations, and communities are implementing innovative strategies, technologies, and programmes that can help curb the spread of malaria. Though these efforts were hampered because of COVID-19, in 2022, the WHO South-East Asia Region renewed its commitment to eliminate malaria by 2030, with countries pledging accelerated action and greater efforts at the sub-national and community levels. Other parts of Asia also progressed well. China was declared Malaria free in June 2021, after 70 years of fighting. In its fights against malaria, Asian countries have recently announced significant investment including a $1.9 million investment in February 2023 by Japan’s GHIT Fund for the research and development of a new malaria drug, and a $1 million contribution by Singapore’s Ministry of Health to the Global Fund to fight AIDS, TB, and Malaria, announced in December 2022. While observing World Malaria day on April 25, let’s explore the current status of Asia’s malaria elimination efforts, highlighting the progress made and strategies needed for a malaria-free future.

Keywords: Maleria,healthcare

For queries, please contact : [email protected] TO SUBSCRIBE SCAN THE QR CODE FROM YOUR MOBILE www.mmactiv.com An publication Comprehensive Ecosystem Coverage Spiraling Growth TRUSTED B2B MEDIA IN BIOTECH, HEALTHCARE & AGRO SECTOR Policy Business Science Technology The only B2B Media for the complete ecosystem of: Nutraceuticals, Dietary Supplements, Functional Foods, Ingredients, Food Processing www.nuffoodsspectrum.in www.biospectrumasia.com Trusted across APAC by Biotech & Healthcare sectors for over a decade BioSpectrum India NuFFooDs Spectrum BioSpectrum Asia AgroSpectrum India Trusted by Biotech & Healthcare sectors in India for over a decade www.biospectrumindia.com Trusted by Agro Sector in India www.agrospectrumindia.com


© 2023 Cell Signaling Technology, Inc. All rights reserved. | All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information. *CiteAb, "What were the 100 most popular antibodies of 2021?" Sept 15, 2022 22-BCH-00056 cellsignal.com We can’t de-risk your entire project. Just one vital part of it. Every therapeutic development project has its pitfalls. But one thing you shouldn’t have to worry about is whether the antibodies you choose will perform as expected. That’s why CST is so fanatical about how we validate our products. We understand that antibodies must be validated in the context of their intended applications. So we validate our antibodies in each assay—independently—and guarantee them to work as expected in those applications. Every time. It’s no wonder that 8 of the top 12 most-cited antibodies come from CST.* Discovery and development scientists around the world trust our products to give them rapid, reproducible results. You can, too. Neuroinflammatory response in Alzheimer’s disease (AD) results in altered morphology of microglia and astrocytes surrounding amyloid-β plaques. This image shows brain from a mouse model of AD labeled with Iba1/AIF-1 antibody #36618 (yellow) and several other relevant targets.


Click to View FlipBook Version